Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Oct:77:103780.
doi: 10.1016/j.breast.2024.103780. Epub 2024 Aug 2.

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

José Enrique Alés-Martínez  1 , Judith Balmaña  2 , Pedro Sánchez-Rovira  3 , Francisco Javier Salvador Bofill  4 , Jose Ángel García Sáenz  5 , Isabel Pimentel  2 , Serafín Morales  6 , María Fernández-Abad  7 , Ainhara Lahuerta Martínez  8 , Neus Ferrer  9 , Pilar Zamora  10 , Begoña Bermejo  11 , Tamara Díaz-Redondo  12 , María Helena López-Ceballos  13 , María Galán  14 , Jhudit Pérez-Escuredo  15 , Laura Calabuig  15 , Miguel Sampayo  15 , José Manuel Pérez-Garcia  16 , Javier Cortés  17 , Antonio Llombart-Cussac  18
Affiliations
Clinical Trial

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study

José Enrique Alés-Martínez et al. Breast. 2024 Oct.

Abstract

Purpose: To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal BRCA mutations (gBRCAm).

Methods: OPHELIA (NCT03931551) was a single-arm, open-label, phase 2 clinical trial. Patients aged ≥18 years diagnosed with HER2-positive ABC with germinal deleterious mutations in BRCA1 or BRCA2 who had received at least one prior systemic regimen for advanced disease were enrolled. Patients received olaparib plus trastuzumab until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was investigator-assessed clinical benefit rate for at least 24 weeks as per RECIST v.1.1. Key secondary endpoints included overall response rate (ORR) and safety profile.

Results: A total of 68 pre-treated HER2-positive ABC patients were screened. Due to slow accrual the trial was stopped after enrolling 5 patients instead of the planned sample size of 20. Four patients achieved clinical benefit (80.0 %, 95 % CI; 28.4-99.5, p < 0.001) and the primary endpoint was met. The ORR was 60.0 % (95 % CI; 14.7-94.7), including one complete response. Four (80.0 %) patients experienced at least one treatment-related treatment-emergent adverse event (TEAE). Most TEAEs were grade 1 or 2. There were no treatment-related deaths and no new safety signals were identified.

Conclusions: This study suggests that the combination of olaparib plus trastuzumab may be effective and safe in pre-treated patients with HER2-positive gBRCAm ABC. This ABC patient population should be further studied and not be pre-emptively excluded from clinical trials of targeted therapy for BRCA1/2-driven cancers.

Keywords: Advanced breast cancer; BRCA mutation; HER2-Positive; Olaparib; Trastuzumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest J.E.A.M. reports receiving travel compensation from AstraZeneca, Roche; and research grants from AstraZeneca. J.B. has participated as invited speaker for AstraZeneca; has institutional, personal and financial interests in AstraZeneca; has institutional and other financial interests in AstraZeneca-MSD; has been involved in educational programs for AstraZeneca-MSD, declares participation in steering committees for AstraZeneca; reports institutional and financial interests in MEDSIR; and declares being a local principal investigator at MEDSIR. J.A.G.S. declares consultative and advisory services for Seagen, AstraZeneca, Daiichi Sankyo, Novaris, Gilead, Menarini; consultancy/speaker fees from Celgene, Eli Lilly, EISAI, MSD, Exact Sciences, Tecnofarma, Nolver (Adium), Asofarma, Roche; institution and research funding from AstraZeneca; and travel support from Gilead, AstraZeneca, Daiichi Sankyo. I.P. reports receiving honoraria from MSD, Novartis, AstraZeneca, Gildead; and consultancy or advisory role for AstraZeneca. M.F.A. declares speakers' bureaus from Daiichi-AstraZeneca, Lilly, Pfizer, Novartis, Eisai; expert testimony for Lilly; and receiving travel expenses from Roche, Novartis. B.B. reports receiving fees for medical education as consulting or advisory role with MSD, Roche, Pierre Fabre, Novartis, Astra Zeneca, Seagen; and speakers' bureau with Pfizer, Roche, MSD, Palex, Eisai, Daichii, Astra Zeneca, Seagen. M.H.L.C. reports speaker honoraria from Daichii, Novartis & Pierre Fabre; and travel and training grants from Roche, Pfizer, MSD & Novartis. J.P.E. is a full-time employee at MEDSIR. L.C. is a full-time employee at MEDSIR. M.S.C. reports participating in an advisory board for Optimapharm, Ability Pharma, and MD Anderson; and is a full-time employee at MEDSIR. J.M.P.G. declares having a consulting or advisory role for Lilly, Roche, Eisai, Daichii Sankyo, AstraZeneca, Seattle Genetics, Gilead, MSD; travel compensation from Roche; and employment at MEDSIR. J.C. reports serving as a consultant/advisor Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp&Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, Expres2ion Biotechnologies, Jazz Pharmaceuticals, Abbvie, BridgeBio; receiving honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca, Gilead, Steamline Therapeutics; research funding to the Institution from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Iqvia, Queen Mary University of London; stock of MEDSIR, MAJ3 Capital, Leuko (relative); travel, accommodation, expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, Gilead, Merck Sharp&Dhome, Steamline Therapeutics; and patents: (1) Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent.Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED. (2) Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/0338368 A1. LICENSED A.L.C. reports receiving research support from Roche, Agendia, Lilly, Pfizer, Novartis, Merck Sharp & Dohme, Gilead, and Daichii-Sanyo; consulting or advisory role for Lilly, Roche, Pfizer, and Novartis; speakers’ bureaus from Lilly, AstraZeneca, Merck Sharp & Dohme; travel support from Roche, Pfizer, AstraZeneca; and stock or other ownership of MEDSIR and Initia-Research. P.S.R., F.J.S.B., S.M., A.L.M., N.F., P.Z., T.D.R., and M.G. declare that they have not conflict of interest.

Figures

Fig. 1
Fig. 1
Waterfall plots of best response (per RECIST v1.1) in patients with HER2-positive advanced breast cancer with germline mutations in BRCA 1/2 treated with olaparib plus trastuzumab. Non-CR/Non-PD; Non-complete response/non-progressive disease; NM, not measurable. *Overall response was partial response by RECIST v.1.1 criteria: complete response in target lesions and non-progressive disease/non-partial response in non-target lesions. **Disappearance of all lesions.
See this image and copyright information in PMC

References

    1. Schlam I., Tarantino P., Tolaney S.M. Overcoming resistance to HER2-directed therapies in breast cancer. Cancers. 2022;14(16):3996. doi: 10.3390/cancers14163996. - DOI - PMC - PubMed
    1. Wang S.S., Jie Y.E., Cheng S.W., Ling G.L., Ming H.V.Y. PARP inhibitors in breast and ovarian cancer. Cancers. 2023;15(8):2357. doi: 10.3390/cancers15082357. - DOI - PMC - PubMed
    1. Pierce A., Mcgowan P.M., Cotter M., et al. Comparative antiproliferative efects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther. 2013;14(6):537–545. doi: 10.4161/cbt.24349. - DOI - PMC - PubMed
    1. Daemen A., Wolf D.M., Korkola J.E., et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat. 2012;135(2):505–517. doi: 10.1007/s10549-012-2188-0. - DOI - PMC - PubMed
    1. García-Parra J., Dalmases A., Morancho B., et al. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. Eur J Cancer. 2014;50(15):2725–2734. doi: 10.1016/j.ejca.2014.07.004. - DOI - PubMed

Publication types

MeSH terms